Tenaya Therapeutics Inc. Common Stock TNYA · Stock Open Tenaya Therapeutics Inc. Common Stock in new tab
Tenaya Therapeutics Inc. Common Stock Analysis (TNYA)
Is Tenaya Therapeutics Inc. Common Stock a good investment? Tenaya Therapeutics Inc. Common Stock (TNYA) is currently trading at 0.7290 USD. Market analysts have a consensus price target of 4.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Tenaya Therapeutics Inc. Common Stock is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -0.41.
Investor FAQ
Does Tenaya Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Tenaya Therapeutics Inc. Common Stock?
Tenaya Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -0.43.
Company Profile
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Community Discussion